PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PharmaTher Holdings Ltd., a specialty pharmaceutical company, has received a Generic Drug User Fee Amendments goal date of October 29, 2024, from the FDA for its Ketamine drug application. The company has addressed previous FDA concerns and is aiming to solve the U.S. ketamine shortage, with plans to pursue international approvals post-launch. PharmaTher’s broader strategy includes exploring new uses and delivery methods for ketamine to treat pain, mental health, and neurological disorders.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.
